• Publications
  • Influence
Bosentan as Adjunctive Therapy for Persistent Pulmonary Hypertension of the Newborn: Results of the Randomized Multicenter Placebo-Controlled Exploratory Trial.
OBJECTIVE To evaluate the efficacy, safety, and pharmacokinetics of the endothelin receptor antagonist bosentan as adjunctive therapy for neonates with persistent pulmonary hypertension of theExpand
  • 27
  • 1
Minimal systemic and high faecal exposure to cadazolid in patients with severe Clostridium difficile infection.
Cadazolid is under development as an oral treatment for Clostridium difficile infection (CDI), which is the most common infectious cause of antibiotic-associated diarrhoea. Low systemic cadazolidExpand
  • 11
  • 1
Pharmacokinetic interactions between the orexin receptor antagonist almorexant and the CYP3A4 inhibitors ketoconazole and diltiazem.
Almorexant, a tetrahydroisoquinoline orexin receptor antagonist and first representative of a new class of compounds for the treatment of insomnia, is a substrate of the cytochrome P450 3A4 isoenzymeExpand
  • 4
  • 1
Abstract 13503: Bosentan as Adjunctive Therapy for Persistent Pulmonary Hypertension of the Newborn: Results of the FUTURE-4 Study
Background: Inhaled nitric oxide (iNO) is the mainstay of therapy for persistent pulmonary hypertension of the newborn (PPHN), but does not fully reverse PPHN in at least 30% of cases. EndothelinExpand
  • 9
A novel CRTH2 antagonist: Single‐ and multiple‐dose tolerability, pharmacokinetics, and pharmacodynamics of ACT‐453859 in healthy subjects
The chemoattractant receptor‐homologous molecule expressed on T‐helper 2 cells (CRTH2) is a G‐protein‐coupled receptor for prostaglandin D2, a key mediator in inflammatory disorders. In thisExpand
  • 15
A bosentan pharmacokinetic study to investigate dosing regimens in paediatric patients with pulmonary arterial hypertension: FUTURE‐3
Aim The aim of the present study was to investigate whether increasing the bosentan dosing frequency from 2 mg kg–1 twice daily (b.i.d.) to 2 mg kg–1 three times daily (t.i.d.) in children withExpand
  • 10
  • PDF
Pharmacokinetic interactions between simvastatin and setipiprant, a CRTH2 antagonist
PurposeSetipiprant, a selective oral CRTH2 antagonist, has been investigated for the treatment of allergic rhinitis and asthma. In vitro data showed that setipiprant has a weak induction potential onExpand
  • 5
Assessment of Peripheral Serotonin Synthesis Using Stable Isotope‐Labeled Tryptophan
Serotonin (5‐HT) is synthesized from dietary tryptophan (Trp) and plays an important role in numerous diseases of the central nervous system and periphery. Stable isotope tracers enable safeExpand
  • 3
Bosentan Pharmacokinetics in Pediatric Patients with Pulmonary Arterial Hypertension: Comparison of Dried Blood Spot and Plasma Analysis
FUTURE-3, a phase III pediatric pharmacokinetic (PK) trial conducted to compare 2 bosentan dosing regimens in 64 patients with pulmonary arterial hypertension, offered the opportunity to compareExpand
  • 5
Formulation development for the orexin receptor antagonist almorexant: assessment in two clinical studies
Almorexant, a dual orexin receptor antagonist, was investigated for the treatment of insomnia. The following observations initiated further formulation development: the active pharmaceuticalExpand
  • 3
  • PDF